Breaking Canadian GLP-1 news
GLP-1 News
Drug approvals, price changes, generic timelines, and clinical trial results affecting GLP-1 medication costs in Canada.
Where are you in your GLP-1 journey?
Answer a few quick questions — get your cheapest path to a GLP-1 prescription, free.
Canada Counterfeit GLP-1 Advisory Meets Generic Supply Gaps
Health Canada advisory RA-81518 warns of unauthorized GLP-1 products as Lilly and Novo Nordisk cite Canadian generic supply constraints in Q2 earnings calls.
Dr. Reddy's, Apotex Eye Global Export of Canada-Approved Generics
Dr. Reddy's has filed for generic semaglutide approval in 80+ countries and Apotex holds tentative FDA approval, using Canada as its first launch market.
Health Canada Warns on Counterfeit GLP-1s as Generic Supply Tightens
Health Canada advisory RA-81518 warns against unauthorized GLP-1 products as Eli Lilly flags significant generic supply constraints in the Canadian market.
TrumpRx US GLP-1 Deal Sets $245 Floor as Canada Awaits Generics
TrumpRx will phase GLP-1 prices from US$350 to US$245 by 2028, but Canadian pharmacy prices already sit lower as generic semaglutide arrives.
Novo Nordisk Aligns Ozempic Price With Generics as Apotex Ships
Novo Nordisk cut Ozempic pricing for uninsured Canadians via a savings card as Apotex began shipping generic semaglutide and Dr. Reddy's expanded distribution.
Health Canada Warns of Counterfeit Ozempic, Mounjaro Sellers
Health Canada advisory RA-81518 flags unauthorized and counterfeit GLP-1 products sold by retailers and online, urging purchases only from licensed pharmacies.
Eight Generic Semaglutide Files Still Under Health Canada Review
Health Canada is reviewing eight additional generic semaglutide submissions after Dr. Reddy's April 28 authorization, with Apotex offering full SKU parity to Ozempic.
Lilly Q2 Mounjaro Sales Hit US$9.94B as Canada Generics Emerge
Eli Lilly reported US$9.94B in Q2 Mounjaro sales as executives flagged Canadian generic supply constraints and Novo Nordisk defended volumes via savings cards.
Lilly, Novo Cite Canadian Generic Competition in Q2 Earnings
Novo Nordisk and Eli Lilly executives addressed Canadian generic competition in Q2 earnings calls, citing savings cards and supply constraints among generic entrants.
BMJ: Canada Second Country Globally to Approve Generic Semaglutide
BMJ reports Canada is only the second country worldwide to approve generic semaglutide, following Health Canada nods to Dr. Reddy's and Apotex.
The $250 Fee: How a Lapsed Patent Opened Canada's Generic Market
Novo Nordisk stopped paying a $C250 annual patent maintenance fee in 2018, a decision that ultimately let generic semaglutide reach Canadian pharmacies in 2026.
Novo Nordisk Forecasts 2026 Sales Drop as Lilly Projects $83B
Novo Nordisk projects a 5-13% 2026 sales decline while Eli Lilly forecasts $80-83B, as generic semaglutide reaches Canadian pharmacies.
pCPA Tiered Pricing: How Generic Semaglutide Prices Will Fall
Canada's pCPA pricing tiers set generic semaglutide at 75-85% of brand for the first entrant, dropping to 35% once three or more generics reach the market.
Rexall Launches Home Delivery of Ozempic, Wegovy, Rybelsus
Rexall and Novo Nordisk Canada launch Novo Nordisk Care Rx home delivery for Ozempic, Wegovy and Rybelsus across all provinces and territories except Quebec.
Novo Nordisk Ozempic Savings Card Targets Uninsured Canadians
Novo Nordisk Canada launches a savings card for Ozempic aligning brand pricing with generics for uninsured Canadians, excluding Quebec, via Rexall pharmacies.
Novo Nordisk Guides 5-13% Revenue Drop as Canada Generics Bite
Novo Nordisk forecasts a 5-13% revenue decline in 2026 as Canadian generic semaglutide reaches pharmacies and the company rolls out a savings card outside Quebec.
Doustdar Calls Wegovy Pill a 'Must-Win' as Canada Generics Land
Novo Nordisk CEO Mike Doustdar frames the oral Wegovy launch as a must-win 2026 battle as Canadian generic semaglutide from Dr. Reddy's and Apotex ships.
Health Canada Backlog Tops 500 Files as Semaglutide Queue Sits at 7
The CGPA says over 500 generic submissions sit at Health Canada with 100+ backlogged, while seven generic semaglutide files still await decisions.
Novo Nordisk's Oral Wegovy Approved in U.S. as 2026 Fight Begins
Novo Nordisk secured U.S. approval for an oral Wegovy pill in December 2025, setting up a 2026 competitive battle with Eli Lilly's orforglipron.
Plan Sponsors Brace for Canada's 65% Semaglutide Price Trigger
Canadian benefits plans face a 65% list-price cut once a third generic semaglutide launches, with Sandoz now targeting Q3 2026 and Aspen going Canada-first.
Looking for current pharmacy prices?
Compare GLP-1 prices across Canada